N/A N=204 Safety & Prevention Outcomes Study
Drug Overdose · Opioid-Related Disorders
Primary: Overdose Risk Behavior — -1.54; -0.51 Scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=395 Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Use Disorder
Opiate Antagonist Overdose · Opioid-Related Disorders
Primary: To Measure the Association of Take-home Naloxone With Overdose Reversals Performed by Patients With Opioid Use Disorder Enrolled in an Opioid Treatment Program — 73; 263…
N/A N=76 Evaluation of a Computerized Opioid Overdose Prevention Program
Computer + Fluency · Computer Only · Treatment as Usual
Primary: Knowledge Gain — 30.6; 30.5; 27.56; 40.7 units on a scale
N/A N=190 Opioid Prescribing After Cesarean Delivery
Surgery · Opioid Use
Primary: Unused Opioids — 5; 10 oxycodone 5mg tablets
N/A N=43 Preventing Overdose Using Information and Data From the Environment
Opioid Overdose · Drug Overdose
Primary: Cumulative Incidence of Accidental Fatal and Non-Fatal Drug Overdoses — 43.5; 37.1 Overdoses per 10,000 residents
Phase 4 N=256 Project OOPEN: Opioid Overdose Prevention, Education and Intervention
Opioid Overdose
Primary: Rate of Fatal Opioid Overdose — 2; 6 Participants
Phase 1 N=24 PP100-01 (Calmangafodipir) for Overdose of Paracetamol
Paracetamol Overdose
Primary: Safety Events — 6; 6; 6; 6 participants
N/A N=299 Primary Care Intervention to Reduce Prescription Opioid Overdoses
Pain · Drug Overdose · Opioid Use Disorders
Primary: Overdose Risk Behaviors — 1.31; 1.21; 1.45; 1.25 score on a scale
Phase 4 N=319 Increasing Naloxone Access for Persons Who Use Opioids
Naloxone
Primary: The Number of Participants That Completed the Training in 6 Months — 55; 56; 10; 9 Participants
N/A N=268 Repeated-dose Behavioral Intervention to Reduce Opioid Overdose
Opioid-Related Disorders · Drug Overdose
Primary: Number of Overdose Events — 0; 0 overdoses
N/A N=150 Peer Intervention to Link Overdose Survivors to Treatment (PILOT)
Opioid Overdose
Primary: Number of Self-reported Overdose Risk Behaviors at 180 Days (6 Months) After Index ED Admission — 4.5; 5.6 units on a scale — p=0.399
N/A N=60 Smartphone Intervention for Overdose and COVID-19
Substance Use Disorders · Overdose · COVID-19
Primary: Content Completion Rate Assessed as Number of Participants Who Completed at Least 6 of the 12 Weeks of the Intervention — 40 Participants
Phase 2 N=30 Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
Opioid Abuse
Primary: Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min) — 11.7; 14.7 score on a scale
N/A N=105 Preventing Opioid Overdose Mortality in the United States
Opioid Overdose
Primary: Naloxone Coverage (Consistency) — 0.9; 0.4 proportion of participants — p=<0.01
Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
N/A N=97 User Acceptability of a Device-Based Opioid Overdose Intervention
Opioid Overdose · Opioid-use Disorder · Substance Use Disorders
Primary: Community Need for a Device-based Opioid Overdose Intervention — 69; 22 Participants
N/A N=321 Subthreshold Opioid Use Disorder Prevention (STOP) Trial
Opioid-use Disorder
Primary: Days of Risky Opioid Use in Past 180 Days — 12.2; 15.5 days
N/A N=2,272 Drug Use Investigation of Jzoloft.
Panic Disorder · Depression
Primary: Number of Participants of Treatment Related Adverse Events (TRAEs) — 263 participants
Phase 2 N=22 Single Dose IV Methadone for Post-Op Pain
Pain, Postoperative
Primary: Pharmacokinetics (PK) in Adults - Systemic Clearance (CL) — 6.14 liters/hour
N/A N=115 Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder: Supplement to COMPUTE 2.0
Opioid Use · Opioid-use Disorder · Suicide
Primary: Number of Participants With CSSRS Completion on the Same Day or in the 14 Days Following Any Outpatient Visit — 14; 8 Participants
Phase 1 N=42 OTR Tablet 40 mg Fed-state Bioequivalence Study
Chronic Pain
Primary: Cmax of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State — 86.15; 63.54 ng/ml
N/A N=196 Discharge Opioid Education to Decrease Opioid Use After Cesarean
Opioid Use
Primary: Opioid Use — 7.5; 10 hydrocodone tablets
N/A N=60 Medication-overuse Headache: 4 Years Follow up
Medication Overuse Headache
Primary: Change in Headache Days/Month After 4 Years Compared to Baseline — 6.6 headache days/month
N/A N=81 SafetyNet Program for Opioid Use Disorder (OUD)
Opioid-Use Disorder (OUD)
Primary: Frequency of Positive Urine Tests at 30 Days (Chart Review) — 35; 45; 1; 0 Participants
N/A N=253 Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program
Opioid Overdose
Primary: Number of Opioid-related Adverse Events — 4.15; 3.24 Events
N/A N=131 Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD
Opioid Use Disorder · Pregnancy Related · Substance Use
Primary: Medication for Opioid Use Disorder (MOUD) Knowledge Score — 83.5; 72.0 percentage of correct answers
N/A N=1,307 Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)
Buprenorphine · Naloxone · Opiate-related Disorders
Primary: Number of Patients Reporting Misuse (Injection, Sniffing, Dose Fractionation, Modification of Prescribed Doses, and Combination With Psychotropic Agents) — 131; 20; 15…
Phase 2 N=12 Buprenorphine's Dose Response Curve
Opioid-related Disorders
Primary: Peak Change From Baseline in Drug Effect Assessed by Visual Analog Scale (VAS) — 17.75; 27.25; 29.63; 58.25 units on a scale
Phase 2 N=49 Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
Opioid Abuse
Primary: Drug Liking at .5 Hours — 66.0; 74.7; 47.7; 40.9 score on a scale
Phase 3 N=199 Naloxone for Optimizing Hypoxemia Of Lung Donors
Brain Death · Organ Donors · Lung Transplantation
Primary: Change in Oxygenation (P/F Ratio) From Baseline to Final Pre-recovery Arterial Blood Gas (ABG) — 81; 80 mm Hg